AI Assistant
Blog
Pricing
Log In
Sign Up
A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma
Details
Cite
Export
Add to List
The content you want is available to Zendy users.
Already have an account? Click
here.
to sign in.
